Overexpression of DNA Polymerase ζAffects Cisplatin Resistance in Ovarian Cancer: An Immunohistochemical Study by NAGASHIMA Minoru et al.
Showa Univ J Med Sci 25（2）, 109～118, June 2013
Overexpression of DNA Polymerase ζ Affects Cisplatin Resistance 
in Ovarian Cancer : An Immunohistochemical Study
Minoru NAGASHIMA1）, Tsuyoshi OKUDA1）, Masaaki NAGATSUKA1）,  
Miki KUSHIMA2）, Takahiko TONOIKE 2） and Takashi OKAI1）
Abstract : DNA polymerase ζ （Pol ζ） participates in translesional bypass 
replication.  Pol ζ has been shown to be an important contributor to cis-
diamminedichloroplatinum（Ⅱ） （DDP ; cisplatin）-induced genomic instability 
and the subsequent emergence of resistance in vitro.  We immunohistochemically 
examined the expression of Pol ζ in ovarian cancer tissues to determine whether 
its expression affects the DDP resistance of human ovarian cancers and also to 
determine whether Pol ζ expression is a prognostic factor for ovarian cancers.  
We assessed 76 archival, formalin-fixed, paraffin-embedded tissue samples obtained 
from patients with epithelial ovarian cancers who underwent their first operation 
between 2003 and 2011.  An ovarian cancer tissue array was also used in this 
study.  Immunohistochemical staining of Pol ζ was performed using an anti-human 
Pol ζ monoclonal rabbit antibody.  The strength of expression of Pol ζ was 
compared with the DDP resistance and clinical features of the study population.  
The Pol ζ over-expression in ovarian cancer tissue which compared with epithelial 
cells in normal ovaries was not affected by the histological types, FIGO stage, or 
patient age, but Pol ζ was significantly more overexpressed in the DDP-resistant 
group than in the DDP-sensitive group （P＝0.043）.  Pol ζ over-expression did not 
significantly affect the survival rate of the ovarian cancer patients ; however, the 
Pol ζ positive group tended to have a poorer long-term prognosis.  In conclusion, 
ovarian carcinoma patients with Pol ζ over-expression are likely to be resistant to 
DDP, especially in cases of recurrent disease.  These results confirm the previous 
findings in vitro, wherein Pol ζ modulated the cytotoxicity and mutagenicity of 
DDP.
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Introduction
　Cis-diamminedichloroplatinum（Ⅱ） （DDP ; cisplatin） is one of the major chemotherapeutic 
agents widely used for the treatment of a broad range of malignant diseases, including testicular, 
ovarian, lung, and bladder cancers 1）.  However, the use of DDP is sometimes limited by its 
severe side effects and the development of resistance.  DDP exerts antitumor effects by forming 
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intra-strand and inter-strand cross-links in DNA.  The most abundant lesions produced in DNA 
by DDP are intra-strand cross-links, which are believed to be important to both the cytotoxicity 
and the mutagenicity of the drug 2）.  When the platinum combines with DNA, some cells 
undergo apoptosis, but some cells are able to repair the DNA and continue proliferating.
　DNA damage induced by both exogenous and endogenous insults is usually repaired by vari-
ous DNA repair mechanisms 3） before DNA replication is initiated.  However, when the DNA 
lesions cannot be completely repaired4）, the major replicative DNA polymerases are unable to 
carry out translesional synthesis.  The mutations generated during translesional synthesis are 
thought to contribute to malignant transformations 5）.  A family of DNA polymerases that can 
mediate such translesion bypass synthesis has been identied in mammalian cells, and includes 
Polymerase ζ （Pol ζ）, Pol η, Pol κ, Pol μ, and Pol ι6）.  Multiple translesion DNA synthesis 
（TLS） polymerases are implicated in the lesion bypass of DNA intra-strand cross-links, including 
those generated by DDP.  Replicative bypass of DDP adducts requires the cooperative actions 
of at least three TLS Pol isoforms : Pol η, REV1, and Pol ζ7-16）.  A reduction in Pol ζ or 
REV1 function renders cells more sensitive to the cytotoxic effects of DDP, and also markedly 
decreases its mutagenicity in vitro11，14）.  These results suggest that Pol ζ or REV1 or both are 
responsible for the ability of cells to replicate their DNA and survive in the presence of a large 
DDP adduct load and that TLS is important for the mutagenicity of DDP and its ability to 
generate drug-resistant variants in the surviving population of cells11）.  However, the function of 
the bypass polymerase involved in TLS in human cancer tissues remains poorly understood.  
　In the present study, we evaluated the localization of Pol ζ in ovarian cancer tissues, and 
examined the relationship between Pol ζ and the clinical outcome of ovarian cancer patients.
Materials and Methods
Patients and Tissue Samples.
　In this prospective study, patients with ovarian cancer were eligible for inclusion if they 
underwent cytoreductive surgery at Showa University Hospital between 2003 and 2011 
（76 cases）.  This study was approved by the Ethics Committee of Showa University of 
Medicine.  The subjects included 23 cases of serous cystoadenocarcinoma, 9 cases of mucinous 
cystoadenocarcinoma, 12 cases of endometrioid adenocarcinoma, 23 cases of clear cell 
adenocarcinoma, and 9 cases of the other kinds of ovarian cancer.  Tissue samples were obtained 
during surgery and processed into paraffin-embedded blocks.  In all cases, hematoxylin-and-eosin–
stained slides were examined to confirm the original diagnosis and to select paraffin blocks with 
representative tumor tissue.
　The clinical stages of ovarian cancer were determined according to the FIGO staging system. 
The numbers of patients with each surgical stage of ovarian cancer were as follows : stage Ⅰ, 23 
cases ; stage Ⅱ, 3 cases ; stage Ⅲ, 40 cases ; stage Ⅳ, 10 cases.  Follow-up information on patient 
survival was obtained from the beginning of the study until November 30, 2012, via direct 
contact with the patients or their families.  According to the NCCN Clinical Practice Guidelines 
in Ovarian Cancer, the recurrent cases were classified into two groups depending on the length 
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of time that had elapsed after platinum-based chemotherapy.  The patients who developed 
recurrent tumors within a year after platinum-based chemotherapy were defined as platinum-
resistant, and the patients who did not possess recurrent tumors were defined as platinum-
sensitive17）.  Only the cases with complete cytoreductive surgery or optimal cytoreductive surgery 
were selected in order to provide a more precise understanding of the effect of chemotherapy. 
After primary cytoreductive surgery, all patients received platinum-based chemotherapy.
Histology
　The histopathological diagnosis was based on the World Health Organization （WHO） 
criteria21）.  The classification was performed using 10 microscopic fields （magnification, ×200） 
from different parts of the primary tumor.
Immunohistochemical Analysis
　The expression of Pol ζ was determined in cases that could be examined by 
immunohistochemical staining.  Formalin-fixed, paraffin-embedded tissue was cut into 3-μm 
sections.  Tissue samples were stained on an autostainer （BenchMark LT, Ventana ; Tucson, 
Arizona, USA） with all steps performed at room temperature.  Antigen retrieval was performed 
in CC1 buffer for 60 min before immunostaining.  A monoclonal rabbit anti-human DNA 
polymerase ζ （Assay Biotechnology ; Sunnyvale California, USA）（1 : 100 dilution） was used 
as the primary antibody and tissue slides were incubated in this antibody for 32 min.  These 
sections were further incubated with an iVIEW DAB universal kit.  Positive and negative 
staining controls were included in each staining run.  Negative control sections had not been 
exposed to the primary antibody.  In all positive controls, the Pol ζ staining was localized to the 
cell cytoplasm and nucleus.
　Staining was assessed using a consulting microscope （Model BX50 ; Olympus, Tokyo, 
Japan）, by three of the authors （MN, TO, MK）, none of whom had prior knowledge of the 
clinical or follow-up data of the patients.  The relationships between these results and the 
clinicopathological variables were analyzed.
　Positive staining for Pol ζ was expressed as the percentage of positive cells on the whole 
surface of the slide, and was semiquantified according to the following grading system : the 
extent of the area stained in the cancer tissues was scored as 0 （＜ 25％）, 1 （25％～ 49％）, 2 
（50％～74％）, or 3 （≧75％）, where 0 and 1 were deemed negative and 2 and 3 were considered 
to be positive.
Statistical evaluation 
　The statistical analysis was performed with the SPSS Statistics 20 software program （SPSS 
IBM ; Chicago, IL, USA）.  Associations were tested by Fisher’s exact test, the Chi-square test, 
or the Wilcoxon signed-rank test.  Survival curves were generated according to the Kaplan-Meier 
method.  Statistical significance was established at P values less than 0.05.  All P values were 
calculated by the logrank test.
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Results
　Fig. 1 A～D show representative specimens of ovarian clear cell adenocarcinoma obtained 
from 45-year-old, 68-year-old, 32-year-old, and 41-year-old patients, respectively.  The 
immunohistochemical staining of Pol ζ was localized in the cytoplasm and was weak in the 
nucleus of carcinoma cells.  The specimens （A to D） were scored 0 to 3, respectively.
　Pol ζ positive cells were present in 78％ of serous adenocarcinomas, 67％ of mucinous 
adenocarcinomas, 83％ of endometrioid adenocarcinomas, and 57％ of clear cell adenocarcinomas 
（Table 1）.  There were no statistically significant differences in the prevalence of Pol ζ staining 
Fig. 1.  Examples of immunohistochemical analysis of Pol ζ expression in paraffin-embedded 
samples of human ovarian clear cell carcinoma. A, score 0 ; B, score 1 ; C, score 2 ; and 
D, score 3. Magnification, ×200
Table 1.  Positive staining rate for Pol ζ in each histological type （N＝ 67）
Histological type Positive staining rate Number
　Serous adenocarcinoma 78％ 23
　Mucinous adenocarcinoma 67％  9
　Endometrioid adenocarcinoma 83％ 12
　Clear cell adenocarcinoma 57％ 23
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among the different types of ovarian cancer by Fisher’s exact test.
　No significant association was observed between the expression of Pol ζ and FIGO stage 
or patient age by Fisher’s exact test （Tables 2 and 3, respectively）.  In contrast, when cases of 
recurrence were evaluated, the DDP-resistant group had a higher positive staining rate than the 
DDP-sensitive group by the Chi-square test （P＝ 0.043 ; Table 4）.
　In patients who underwent surgery after recurrence, we examined the positive staining rate 
of the surgical specimens from both the primary debulking surgery （PDS） and secondary 
debulking surgery （SDS）.  There were no significant differences in the prevalence of Pol ζ 
staining between the PDS （75％ Pol ζ positive） and SDS （100％ Pol ζ positive） samples by 
the Wilcoxon signed-rank test （Table 5）.
　We examined the prognoses of the cases in relation to the differences in the staining for Pol 
ζ .  Only the cases with complete cytoreductive surgery or optimal cytoreductive surgery were 
evaluated.  The study was carried out separately for patients with early stage （stage Ⅰ/Ⅱ） and 
advanced stage （stage Ⅲ /Ⅳ） disease.  There were no significant differences in the progression-
free survival and overall survival between the Pol ζ positive group and negative group, 
regardless of the stage （Fig. 2）.
Discussion
　The mechanism（s） by which cells become resistant to platinum-containing chemotherapeutic 
agents are still poorly defined.  However, the incidence of drug-resistant strains increases when 
the drug is administered repeatedly to the same cells in experiments using cell lines.  The DDP-
Table 2.  Positive staining rate for Pol ζ at each FIGO 
stage. （N＝ 96）
Stage Positive staining rate Number
Ⅰ 61％ 23
Ⅱ 67％  3
Ⅲ 70％ 40
Ⅳ 80％ 10
Table 3.  Positive staining rate for Pol ζ at each age. （N＝ 76）
Age Positive staining rate Number
30’s 67％  6
40’s 61％ 18
50’s 65％ 26
60’s 81％ 16
70’s 70％ 10
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resistant phenotype is the result of genetic changes, and it is known that the TLS pathway plays 
a role in producing these genetic changes.  Specifically Pol ζ or REV1 or both is considered 
to be important in this pathway in human cells11，14，18）.  Disabling REV1 function slowed the 
emergence of resistance to DDP in a human ovarian carcinoma line14）.  Similar changes in 
phenotype have been observed in a human fibroblast line expressing antisense RNA to hREV3, 
the catalytic subunit of Pol ζ11）.  However, the role of TLS function in DDP resistance in 
human carcinoma tissue is still poorly understood.  The results of the present study indicate that 
Pol ζ plays a role in the resistance of human ovarian carcinoma to DDP.  
　The cytotoxicity of DDP to cells in vitro is proportional to the extent of DDP adduct 
Table 4.  Clinical background of the DDP-sensitive and -resistant patients with recurrent ovarian cancer
DDP-sensitive group（N＝11） DDP-resistant group（N＝19） P value＊
Age （years）  52.1 ±  7.1  56.7 ± 10.6 0.22
Height （cm） 152.7 ±  6.7 154.7 ±  5.5 0.38
Weight （kg）  56.5 ± 14.0  50.0 ±  7.9 0.12
BMI  24.3 ±  6.2  20.9 ±  3.0 0.052
CA125 （U/ml） 1464 ± 1720 2429 ± 4083 0.48
（before treatment）
Stage
__Ⅰ 18.2 ％（2） 10.5％（2） 0.61
__Ⅱ 0 5.3％（1） ＞ 0.99
__Ⅲ 72.7 ％（8） 63.2％（12） 0.70
__Ⅳ 9.1％（1） 21.1％（4） 0.63
Pathology  
__Serous 36.4％（4） 42.1％（8） ＞ 0.99
__Mucinous 9.1％（1） 5.3％（1） ＞ 0.99
__Endometrioid 0 5.3％（1） ＞ 0.99
__Clear cell 27.3％（3） 26.3％（5） ＞ 0.99
__Others 27.3％（3） 21.1％（4） ＞ 0.99
NAC 54.5％（6） 26.3％（5） 0.24
Surgery
__Complete 9.1％（1） 21.1％（4） 0.63
__Optimal 90.9％（10） 78.9％（15） 0.62
Positive
staining rate 30.0％（3） 75.0％（10） 0.043
＊Chi-square test.
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formation in DNA, and cells with defects in nucleotide excision repair, the major DNA repair 
mechanism that removes these adducts, are hypersensitive to DDP19, 20）.  Impairment of hREV1 
or Pol ζ function in cells causes an increase in sensitivity to the cytotoxic effect of DDP14）.  
　Clinically, the effect of platinum-containing drugs in ovarian cancer is dependent on the 
different histological types.  Usually, serous and endometrioid adenocarcinomas are comparatively 
sensitive to DDP, whereas mucinous and clear cell adenocarcinomas are resistant to DDP.  In 
the current study, the Pol ζ overexpression in ovarian cancer tissue was not related to the 
histological types.  This suggests that the Pol ζ-related error-prone replication system is not 
involved in the differences in the sensitivity of the different histological types of ovarian cancers 
to DDP.
　In recurrent ovarian cancers, the response rate to chemotherapy is correlated with the disease-
free interval.  We compared the surgical specimens of PDS and SDS from the same cases, all of 
whom had relapsed after chemotherapy, in order to investigate the acquisition of drug resistance 
of the tissues after chemotherapy.  We found that the positive staining rate for Pol ζ was 100％ 
（all 12 cases） in the surgical specimens of SDS.  Because 9 of these cases were also positive in 
the PDS specimens, there was no statistically significant difference in the positive staining rate 
of the two groups ; however, the fact that all of the SDS specimens were positive suggested the 
possibility that the exposure to chemotherapy was involved in the acquisition of drug resistance.
Table 5.  Differences in the positive staining score for Pol ζ between primary debulk-
ing surgery （PDS） and secondary debulking surgery （SDS）.
Cases PDS （score） SDS （score）
Number of 
chemotherapy cycles
 1 Positive （2） Positive （2） 4
 2 Positive （3） Positive （3） 6
 3 Positive （3） Positive （2） 6
 4 Negative （1） Positive （2） 6
 5 Positive （3） Positive （2） 6
 6 Positive （3） Positive （2） 6
 7 Negative （1） Positive （2） 4
 8 Positive （2） Positive （2） 6
 9 Positive （2） Positive （3） 12
10 Positive （2） Positive （2） 11
11 Negative （0） Positive （2） 9
12 Positive （2） Positive （2） 8
The extent of the area stained in the cancer tissues was scored as 0 （＜ 25％）, 1 
（25％～ 49％）, 2 （50％～ 74％）, or 3 （≧ 75％）, where 0 and 1 were deemed nega-
tive and 2 and 3 were considered to be positive.
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　In the current study, the Pol ζ over-expression in the DDP-resistant group was significantly 
higher than that in the DDP-sensitive group.  However, Pol ζ over-expression was not related to 
FIGO staging.  The present results support those of in vitro studies, in which Pol ζ modulated 
the cytotoxicity and mutagenicity of DDP11）.
　We examined the association between the clinical variables and Pol ζ expression to assess 
its potential prognostic significance.  There were no significant differences between the clinical 
variables with regard to the Pol ζ expression in the ovarian cancer patients.  Moreover, Pol ζ 
over-expression did not significantly affect the survival of the ovarian cancer patients.  However, 
the Pol ζ-positive group tended to have a poorer long-term prognosis.  This is the only study 
to analyze Pol ζ protein in human tissue.  For the detailed understanding of the TLS pathway 
in the DDP resistance in human, further studies including REV1 or related TLS pathway 
proteins are required.
　In conclusion, ovarian carcinoma patients with Pol ζ over-expression are considered likely 
Fig. 2.  Kaplan Meier Curves for progression-free survival and overall survival comparing Pol ζ 
positive group versus Pol ζ negative group.
A, B. Patients with early stage cancer （stagesⅠandⅡ） analyzed for progression-free 
survival （A） and overall survival （B）. C, D. Patients with advanced stage cancer （stages 
Ⅲ and Ⅳ） analyzed for progression-free survival （C） and overall survival （D）.
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to have resistance to DDP, especially in the recurrent state.  This is the first report of the 
Pol ζ-related error-prone replication system in human tissues of cancer patients.  Based on 
our present findings and those of previous studies, Pol ζ is an attractive target for therapeutic 
investigation to simultaneously enhance DDP sensitivity and reduce the risk of developing drug 
resistance.  Studies are now needed to examine how the expression of Pol ζ varies among 
different types of tumors and whether its expression is linked to the clinical response.
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